1-12 of 12
Isabelle Vande Broek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma

Michel Delforge, Marie-Christiane Vekemans, Sébastien Anguille, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Danielle Strens, Sandra Van Hoorenbeeck, Evelien J Moorkens, Joris Diels, Francesca Ghilotti, Sander Dalhuisen, Sophie Vandervennet
Journal: Blood
Blood (2021) 138 (Supplement 1): 4075.
https://doi.org/10.1182/blood-2021-146250
Published: 2021
Journal Articles

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Inge Oudaert, MSc, Sylvia Faict, MSc, Ludovic D'Auria, PhD, Jonas Dehairs, PhD, Ken Maes, Philip Vlummens, MD, Lotte Jacobs, BSc, Kim De Veirman, Elke De Bruyne, PhD, Karel Fostier, MD, Isabelle Vande Broek, MD PhD, Rik Schots, Karin Vanderkerken, PhD, Johannes V. Swinnen, PhD, Eline Menu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3058.
https://doi.org/10.1182/blood-2019-122857
Published: 2019
Journal Articles

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

Maximilian Merz, Isabelle Vande Broek, MD PhD, Manuel Pérez, Dr., Brigitte Kolb, MD, Argiris Symeonidis, MD PhD, Emmanouil Nikolousis, Athanasios Zomas, Francisco Gonzalez, Lenka Kellermann, BS, MBA, Hartmut Goldschmidt
Journal: Blood
Blood (2019) 134 (Supplement_1): 3115.
https://doi.org/10.1182/blood-2019-122706
Published: 2019
Journal Articles

Darbepoetin Alfa for the Treatment of Anemic Patients with Myelodysplastic Syndrome: A Belgian Single-Arm, Companion Trial to the Arcade Phase 3 Study

Michel Delforge, Dominiek Mazure, Isabelle Vande Broek, Jo Caers, Sejal Badre, Bhakti Mehta, Cisio De Oliveira Brandao
Journal: Blood
Blood (2017) 130 (Supplement 1): 5318.
https://doi.org/10.1182/blood.V130.Suppl_1.5318.5318
Published: 2017
Journal Articles

Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma

Charalampia Kyriakou, MD PhD, Philip Murphy, MD, Maria Teresa Petrucci, MD, Pamela Bacon, Philip Lewis, Hélène Gilet, MSc, Benoit Arnould, PhD, Isabelle Vande Broek, MD PhD, Xavier Leleu, MD
Journal: Blood
Blood (2015) 126 (23): 2085.
https://doi.org/10.1182/blood.V126.23.2085.2085
Published: 2015
Journal Articles

Psychometric Performance Of The EORTC Quality-Of-Life Core Questionnaire (QLQ-C30) and QLQ-Multiple Myeloma (QLQ-MY20) In Relapsed/Refractory Multiple Myeloma (RRMM)

Xavier Leleu, MD, PhD, Maria Teresa Petrucci, MD, Manfred Welslau, Isabelle Vande Broek, Philip T Murphy, MD, MRCPath, Andrew Bottomley, PhD, Pamela Bacon, Philip Lewis, PhD, Hélène Gilet, MSc, Benoit Arnould, PhD, Charalampia Kyriakou
Journal: Blood
Blood (2013) 122 (21): 1721.
https://doi.org/10.1182/blood.V122.21.1721.1721
Published: 2013
Journal Articles

Continued Treatment Duration, Drug dosing  and Health-Related Quality Of Life (HRQoL) Of Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Receiving 2 nd and 3 rd Line Treatments: Results From a European Multicentre Study

Maria Teresa Petrucci, MD, Xavier Leleu, MD, PhD, Charalampia Kyriakou, Isabelle Vande Broek, PhD, Philip T Murphy, MD, MRCPath, Philip Lewis, PhD, Pamela Bacon, Benoit Arnould, PhD, Manfred Welslau
Journal: Blood
Blood (2013) 122 (21): 5368.
https://doi.org/10.1182/blood.V122.21.5368.5368
Published: 2013
Journal Articles

Impaired Osteogenic Differentiation of Mesenchymal Stem Cells Derived From Multiple Myeloma Patients Is Associated with a Failure In the Deactivation of the NOTCH Pathway

Song Xu, Jinsong Hu, Dehui Xu, Isabelle Vande Broek, Xavier Leleu, Ben Van Camp, Karin Vanderkerken, Ivan Van Riet
Journal: Blood
Blood (2010) 116 (21): 1894.
https://doi.org/10.1182/blood.V116.21.1894.1894
Published: 2010
Journal Articles

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

Brief Report
Jinsong Hu, Damian R. Handisides, Els Van Valckenborgh, Hendrik De Raeve, Eline Menu, Isabelle Vande Broek, Qian Liu, Jessica D. Sun, Ben Van Camp, Charles P. Hart, Karin Vanderkerken
Journal: Blood
Blood (2010) 116 (9): 1524–1527.
https://doi.org/10.1182/blood-2010-02-269126
Published: 2010
Includes: Supplemental data
Journal Articles

Hypoxia Activated Prodrug TH-302 for the Treatment of Multiple Myeloma.

Jinsong Hu, Damian R Handisides, Els Van Valckenborgh, Hendrik De Raeve, Eline Menu, Isabelle Vande Broek, Qian Liu, Jessica D Sun, Ben Van Camp, Charles Hart, Karin Vanderkerken
Journal: Blood
Blood (2009) 114 (22): 3838.
https://doi.org/10.1182/blood.V114.22.3838.3838
Published: 2009
Journal Articles

International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.

Michel Delforge, MD, PhD, Hadewijch De Samblanx, Hilde Demuynck, Greet Bries, Philippe Mineur, Nathalie Meuleman, Fritz Offner, Chantal Doyen, Walter Feremans, Ann Van de Velde, Christophe Ravoet, Isabelle Vande Broek, Jan Van Droogenbroeck, Gabry Kuijten-Celzo, Joris Diels, Rita Ganguly, Ravinder Dhawan
Journal: Blood
Blood (2009) 114 (22): 4523.
https://doi.org/10.1182/blood.V114.22.4523.4523
Published: 2009
Journal Articles

Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma.

Isabelle Vande Broek, MD, PhD, Xavier Leleu, Dan Duda, MD, PhD, Benjamin Van Camp, MD, PhD, Karin Vanderkerken, Ivan van Riet, PhD
Journal: Blood
Blood (2009) 114 (22): 2807.
https://doi.org/10.1182/blood.V114.22.2807.2807
Published: 2009